Infection-Phase Biomolecular Coronas in Inhaled Nanomedicine.

Authors

Zhenchao Wu, Taikang Yao, Ning Shen

Published in

Advanced healthcare materials. Pages e71853. Oct 14, 2026. Epub Oct 14, 2026.

Abstract

An inhaled nanomedicine encounters two successive forms of remodeling: device-related changes during aerosol generation and biological conditioning after deposition. Respiratory infection adds a moving interface, as epithelial secretion, surfactant composition, plasma leakage, and neutrophil-derived material vary across airway compartments and over time. Pulmonary and disease-corona studies already establish that host environments influence nanoparticle identity. The next question is how this knowledge should change formulation selection and dosing for infected lungs. We propose an infection-phase framework based on measured, overlapping airway environments. It connects the post-aerosol particle to its surface-associated biomolecules, distinguishes this interface from aggregation and bulk mucus effects, and links analytical measurements to functional delivery. A staged research program begins with one compartment and two contrasting environments, then adds controlled particle-transfer experiments, candidate-component perturbation, and donor-level validation. Lipid nanoparticles, polymeric carriers, and nanozymes require different functional endpoints within this shared framework. The immediate translational output is a biorelevant performance stress test that identifies robust or environment-selective formulations and guides the next experiment.

PMID:
42870554
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.